• 1
    BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10(Suppl 3):130.
  • 2
    Doust JA, Glasziou PP, Pietrzak E., et al. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:19781984.
  • 3
    Maisel AS, Krishnaswamy P., Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161167.
  • 4
    McCullough PA, Nowak RM, McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure—analysis from Breathing Not Properly (BNP) multinational study. Circulation 2002;106:416422.
  • 5
    Morrison KL, Harrison A., Krishnaswamy P., et al. Utility of rapid B-natriuretic peptide (BNP) assay in differentiation HF from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202209.
  • 6
    Dao Q., Krishnaswamy P., Nowak RM, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of heart failure in an urgent care setting. J Am Coll Cardiol 2001;37:379385.
  • 7
    Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:13471351.
  • 8
    Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440444.
  • 9
    Luchner A., Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684H1689.
  • 10
    Maeda K., Tsutamoto T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825832.
  • 11
    McDonald KA, Kittleson MD, Munro C., et al. Brain natriuretic peptide concentration in dogs with heart disease and congestive heart failure. J Vet Intern Med 2003;17:172177.
  • 12
    Haggstrom J., Hansson K., Kvart C., et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral valve regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol 2000;2:716.
  • 13
    Asano K., Masuda K., Okumura M., et al. Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. J Vet Med Sci 1999;61:523529.
  • 14
    Doust JA, Pietrzak E., Dobson A., et al. How well does Btype natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ 2005;330:625633.
  • 15
    Koglin J., Pehlivanli S., Schawaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:19341941.
  • 16
    Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386391.
  • 17
    Clerico A., Iervasi G., Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170179.
  • 18
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005;112: 18251852.
  • 19
    Chetboul V., Tessier-Vetzel D., Escriou C., et al. Diagnostic potential of natriuretic peptides in the occult phase of golden retriever muscular dystrophy cardiomyopathy. J Vet Intern Med 2004;18:845850.
  • 20
    Baumwart RD, Meurs KM. Assessment of plasma brain natriuretic peptide concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res 2005;66:20862089.
  • 21
    Eriksson AS, Jarvinen AK, Eklund KK, et al. Effect of age and body weight on neurohumoral variables in healthy Cavalier King Charles Spaniels. Am J Vet Res 2001;62:18181824.
  • 22
    Asano K., Murakami M., Endo D., et al. Complementary DNA cloning, tissue distribution, and synthesis of canine brain natriuretic peptide. Am J Vet Res 1999;60:860864.
  • 23
    McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: Rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003;10:198204.
  • 24
    Thomas CJ, Woods RL. Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. Clin Exp Pharmacol Physiol 2003;30:369375.
  • 25
    Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994. Circulation 2006;113:799805.
  • 26
    Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464469.
  • 27
    Hirata Y., Matsumoto A., Aoyagi T., et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001;51:585591.
  • 28
    Leya FS, Arab D., Joyal D., et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005;45:19001902.
  • 29
    Wolde M., Tulevski II, Mulder JW, et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003;107:20822084.
  • 30
    Leuchte HH, Holzapfel M., Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764770.
  • 31
    Omland T., Aakvaag A., Bonarjee VS, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction—comparison with plasma atrial natriuretic peptide and Nterminal proatrial natriuretic peptide. Circulation 1996;93:19631969.
  • 32
    Detaint D., Messika-Zeitoun D., Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: Determinants and impact on outcome. Circulation 2005;111:23912397.
  • 33
    Gerber IL, Legget ME, West TM, et al. Usefulness of serial measurements of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 2005;95:898901.
  • 34
    Wang TJ, Larson MG, Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655663.
  • 35
    Trouthton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:11261130.
  • 36
    Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647654.
  • 37
    Gackowski A., Isnard R., Golmard JL, et al. Comparison of echocardiography and plasma B-type natriuretic peptide in monitoring the response to treatment in acute heart failure. Eur Heart J 2004;25:17881796.
  • 38
    Kawai K., Hata K., Takaoka H., et al. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: A potential of hormone-guided treatment. Am Heart J 2001;141:925932.
  • 39
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976982.
  • 40
    McCullough PA, Duo P., Omland T., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571579.